Xencor Inc
Closed
SectorHealthcare
12.36 1.48
Overview
Share price change
24h
Min
11.91
Max
12.51
Income | -214M -129M |
|---|---|
Sales | -24M 4.5M |
EPS | -1.71 |
Profit margin | -2,854.65 |
Employees | 260 |
EBITDA | -81M -75M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +100.99% upside |
Next Earnings | 4 Aug 2026 |
|---|
Market Cap | -144M 846M |
|---|---|
Previous open | 10.88 |
Previous close | 12.36 |
Xencor Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Xencor Inc Forecast
Price Target
By TipRanks
100.99% upside
12 Months Forecast
Average 24.3 USD 100.99%
High 38 USD
Low 13 USD
Based on 11 Wall Street analysts offering 12 month price targets forXencor Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Xencor Inc
Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.